ID   SYEP_HUMAN              Reviewed;        1512 AA.
AC   P07814; A0AVA9; B9EGH3; Q05BP6; Q05DF8; Q5DSM1; Q5H9S5; Q6PD57; Q86X73;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   09-FEB-2010, sequence version 5.
DT   26-FEB-2020, entry version 232.
DE   RecName: Full=Bifunctional glutamate/proline--tRNA ligase;
DE   AltName: Full=Bifunctional aminoacyl-tRNA synthetase;
DE   AltName: Full=Cell proliferation-inducing gene 32 protein;
DE   AltName: Full=Glutamatyl-prolyl-tRNA synthetase;
DE   Includes:
DE     RecName: Full=Glutamate--tRNA ligase;
DE              EC=6.1.1.17;
DE     AltName: Full=Glutamyl-tRNA synthetase;
DE              Short=GluRS;
DE   Includes:
DE     RecName: Full=Proline--tRNA ligase;
DE              EC=6.1.1.15 {ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331};
DE     AltName: Full=Prolyl-tRNA synthetase;
GN   Name=EPRS1 {ECO:0000312|HGNC:HGNC:3418};
GN   Synonyms=EPRS, GLNS, PARS, QARS, QPRS; ORFNames=PIG32;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLU-308 AND VAL-1043.
RC   TISSUE=Bone marrow;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLU-308.
RC   TISSUE=Brain, Duodenum, Eye, Lung, Placenta, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 54-1512, AND VARIANTS GLU-308 AND HIS-334.
RX   PubMed=1988429;
RA   Fett R., Knippers R.;
RT   "The primary structure of human glutaminyl-tRNA synthetase. A highly
RT   conserved core, amino acid repeat regions, and homologies with translation
RT   elongation factors.";
RL   J. Biol. Chem. 266:1448-1455(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 62-1512, AND VARIANTS GLU-308 AND
RP   HIS-334.
RA   Kim J.W.;
RT   "Identification of a proliferation inducing gene.";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] OF 168-959, AND VARIANTS GLU-308 AND
RP   HIS-334.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=3290852; DOI=10.1093/nar/16.12.5391;
RA   Thoemmes P., Fett R., Schray B., Kunze N., Knippers R.;
RT   "The core region of human glutaminyl-tRNA synthetase homologies with the
RT   Escherichia coli and yeast enzymes.";
RL   Nucleic Acids Res. 16:5391-5406(1988).
RN   [7]
RP   FUNCTION.
RX   PubMed=1756734; DOI=10.1002/j.1460-2075.1991.tb05005.x;
RA   Cerini C., Kerjan P., Astier M., Gratecos D., Mirande M., Semeriva M.;
RT   "A component of the multisynthetase complex is a multifunctional aminoacyl-
RT   tRNA synthetase.";
RL   EMBO J. 10:4267-4277(1991).
RN   [8]
RP   GENE STRUCTURE.
RX   PubMed=1556743; DOI=10.1007/bf00163851;
RA   Kaiser E., Eberhard D., Knippers R.;
RT   "Exons encoding the highly conserved part of human glutaminyl-tRNA
RT   synthetase.";
RL   J. Mol. Evol. 34:45-53(1992).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10791971; DOI=10.1083/jcb.149.3.567;
RA   Ko Y.G., Kang Y.S., Kim E.K., Park S.G., Kim S.;
RT   "Nucleolar localization of human methionyl-tRNA synthetase and its role in
RT   ribosomal RNA synthesis.";
RL   J. Cell Biol. 149:567-574(2000).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [11]
RP   FUNCTION, AND IDENTIFICATION IN THE GAIT COMPLEX.
RX   PubMed=15479637; DOI=10.1016/j.cell.2004.09.030;
RA   Sampath P., Mazumder B., Seshadri V., Gerber C.A., Chavatte L., Kinter M.,
RA   Ting S.M., Dignam J.D., Kim S., Driscoll D.M., Fox P.L.;
RT   "Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific
RT   silencing of translation.";
RL   Cell 119:195-208(2004).
RN   [12]
RP   INTERACTION WITH DUS2L.
RX   PubMed=15994936; DOI=10.1158/0008-5472.can-05-0600;
RA   Kato T., Daigo Y., Hayama S., Ishikawa N., Yamabuki T., Ito T.,
RA   Miyamoto M., Kondo S., Nakamura Y.;
RT   "A novel human tRNA-dihydrouridine synthase involved in pulmonary
RT   carcinogenesis.";
RL   Cancer Res. 65:5638-5646(2005).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-898, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-872; SER-882; SER-885;
RP   SER-886 AND THR-898, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   SUBUNIT, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19131329; DOI=10.1074/jbc.m809636200;
RA   Kaminska M., Havrylenko S., Decottignies P., Gillet S., Le Marechal P.,
RA   Negrutskii B., Mirande M.;
RT   "Dissection of the structural organization of the aminoacyl-tRNA synthetase
RT   complex.";
RL   J. Biol. Chem. 284:6053-6060(2009).
RN   [20]
RP   SUBUNIT, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=19289464; DOI=10.1074/jbc.m900480200;
RA   Kaminska M., Havrylenko S., Decottignies P., Le Marechal P., Negrutskii B.,
RA   Mirande M.;
RT   "Dynamic Organization of Aminoacyl-tRNA Synthetase Complexes in the
RT   Cytoplasm of Human Cells.";
RL   J. Biol. Chem. 284:13746-13754(2009).
RN   [21]
RP   PHOSPHORYLATION AT SER-886 AND SER-999, AND INTERACTION WITH SYNCRIP.
RX   PubMed=19647514; DOI=10.1016/j.molcel.2009.05.028;
RA   Arif A., Jia J., Mukhopadhyay R., Willard B., Kinter M., Fox P.L.;
RT   "Two-site phosphorylation of EPRS coordinates multimodal regulation of
RT   noncanonical translational control activity.";
RL   Mol. Cell 35:164-180(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-882; SER-886 AND SER-891, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-300; LYS-417; LYS-498; LYS-535;
RP   LYS-542; LYS-637; LYS-788 AND LYS-1503, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1000, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   MALONYLATION AT LYS-300.
RX   PubMed=21908771; DOI=10.1074/mcp.m111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y., He W.,
RA   Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C., Dai J.,
RA   Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [27]
RP   PHOSPHORYLATION AT SER-886.
RX   PubMed=21220307; DOI=10.1073/pnas.1011275108;
RA   Arif A., Jia J., Moodt R.A., DiCorleto P.E., Fox P.L.;
RT   "Phosphorylation of glutamyl-prolyl tRNA synthetase by cyclin-dependent
RT   kinase 5 dictates transcript-selective translational control.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:1415-1420(2011).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-886, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [29]
RP   FUNCTION, RECONSTITUTION OF THE GAIT COMPLEX, AND MUTAGENESIS OF SER-886
RP   AND SER-999.
RX   PubMed=23071094; DOI=10.1128/mcb.01168-12;
RA   Arif A., Chatterjee P., Moodt R.A., Fox P.L.;
RT   "Heterotrimeric GAIT complex drives transcript-selective translation
RT   inhibition in murine macrophages.";
RL   Mol. Cell. Biol. 32:5046-5055(2012).
RN   [30]
RP   IDENTIFICATION IN THE MSC COMPLEX, INTERACTION WITH TARS3, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=24312579; DOI=10.1371/journal.pone.0081734;
RA   Kim K., Park S.J., Na S., Kim J.S., Choi H., Kim Y.K., Paek E., Lee C.;
RT   "Reinvestigation of aminoacyl-tRNA synthetase core complex by affinity
RT   purification-mass spectrometry reveals TARSL2 as a potential member of the
RT   complex.";
RL   PLoS ONE 8:E81734-E81734(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-355; SER-434; SER-747;
RP   SER-882; SER-886; THR-898; SER-998 AND SER-1350, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-1152, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [35]
RP   FUNCTION, INTERACTION WITH SLC27A1, SUBCELLULAR LOCATION, TOPOLOGY, AND
RP   PHOSPHORYLATION AT SER-999 BY RPS6KB1.
RX   PubMed=28178239; DOI=10.1038/nature21380;
RA   Arif A., Terenzi F., Potdar A.A., Jia J., Sacks J., China A., Halawani D.,
RA   Vasu K., Li X., Brown J.M., Chen J., Kozma S.C., Thomas G., Fox P.L.;
RT   "EPRS is a critical mTORC1-S6K1 effector that influences adiposity in
RT   mice.";
RL   Nature 542:357-361(2017).
RN   [36]
RP   INVOLVEMENT IN HLD15, VARIANTS HLD15 339-ARG--TYR-1512 DEL; ARG-1115;
RP   THR-1126 AND SER-1160, AND CHARACTERIZATION OF VARIANTS HLD15 ARG-1115 AND
RP   THR-1126.
RX   PubMed=29576217; DOI=10.1016/j.ajhg.2018.02.011;
RA   Mendes M.I., Gutierrez Salazar M., Guerrero K., Thiffault I.,
RA   Salomons G.S., Gauquelin L., Tran L.T., Forget D., Gauthier M.S.,
RA   Waisfisz Q., Smith D.E.C., Simons C., van der Knaap M.S., Marquardt I.,
RA   Lemes A., Mierzewska H., Weschke B., Koehler W., Coulombe B., Wolf N.I.,
RA   Bernard G.;
RT   "Bi-allelic Mutations in EPRS, Encoding the Glutamyl-Prolyl-Aminoacyl-tRNA
RT   Synthetase, Cause a Hypomyelinating Leukodystrophy.";
RL   Am. J. Hum. Genet. 102:676-684(2018).
RN   [37]
RP   STRUCTURE BY NMR OF 749-805, AND RNA-BINDING.
RX   PubMed=11123902; DOI=10.1021/bi001393h;
RA   Jeong E.-J., Hwang G.-S., Kim K.H., Kim M.J., Kim S., Kim K.-S.;
RT   "Structural analysis of multifunctional peptide motifs in human
RT   bifunctional tRNA synthetase: identification of RNA-binding residues and
RT   functional implications for tandem repeats.";
RL   Biochemistry 39:15775-15782(2000).
RN   [38] {ECO:0000244|PDB:4K86, ECO:0000244|PDB:4K87, ECO:0000244|PDB:4K88}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1000-1512 IN COMPLEXES WITH
RP   SYNTHETIC INHIBITOR HALOFUGINONE; L-PROLINE; ZINC AND ADENOSINE, CATALYTIC
RP   ACTIVITY, FUNCTION, SUBUNIT, AND MUTAGENESIS OF PHE-1097 AND ARG-1152.
RX   PubMed=24100331; DOI=10.1107/s0907444913020556;
RA   Son J., Lee E.H., Park M., Kim J.H., Kim J., Kim S., Jeon Y.H., Hwang K.Y.;
RT   "Conformational changes in human prolyl-tRNA synthetase upon binding of the
RT   substrates proline and ATP and the inhibitor halofuginone.";
RL   Acta Crystallogr. D 69:2136-2145(2013).
RN   [39] {ECO:0000244|PDB:4HVC}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1003-1512 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR; ZINC AND ATP ANALOG, CATALYTIC ACTIVITY, FUNCTION, AND
RP   SUBUNIT.
RX   PubMed=23263184; DOI=10.1038/nature11774;
RA   Zhou H., Sun L., Yang X.L., Schimmel P.;
RT   "ATP-directed capture of bioactive herbal-based medicine on human tRNA
RT   synthetase.";
RL   Nature 494:121-124(2013).
RN   [40] {ECO:0000244|PDB:5A34, ECO:0000244|PDB:5BMU}
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1-175, AND SUBUNIT.
RX   PubMed=26472928; DOI=10.1074/jbc.m115.690867;
RA   Cho H.Y., Maeng S.J., Cho H.J., Choi Y.S., Chung J.M., Lee S., Kim H.K.,
RA   Kim J.H., Eom C.Y., Kim Y.G., Guo M., Jung H.S., Kang B.S., Kim S.;
RT   "Assembly of Multi-tRNA Synthetase Complex via Heterotetrameric Glutathione
RT   Transferase-homology Domains.";
RL   J. Biol. Chem. 290:29313-29328(2015).
CC   -!- FUNCTION: Multifunctional protein which is primarily part of the
CC       aminoacyl-tRNA synthetase multienzyme complex, also know as
CC       multisynthetase complex, that catalyzes the attachment of the cognate
CC       amino acid to the corresponding tRNA in a two-step reaction: the amino
CC       acid is first activated by ATP to form a covalent intermediate with AMP
CC       and is then transferred to the acceptor end of the cognate tRNA
CC       (PubMed:1756734, PubMed:24100331, PubMed:23263184). The phosphorylation
CC       of EPRS1, induced by interferon-gamma, dissociates the protein from the
CC       aminoacyl-tRNA synthetase multienzyme complex and recruits it to the
CC       GAIT complex that binds to stem loop-containing GAIT elements in the
CC       3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin), suppressing
CC       their translation. Interferon-gamma can therefore redirect, in specific
CC       cells, the EPRS1 function from protein synthesis to translation
CC       inhibition (PubMed:15479637, PubMed:23071094). Also functions as an
CC       effector of the mTORC1 signaling pathway by promoting, through SLC27A1,
CC       the uptake of long-chain fatty acid by adipocytes. Thereby, it also
CC       plays a role in fat metabolism and more indirectly influences lifespan
CC       (PubMed:28178239). {ECO:0000269|PubMed:15479637,
CC       ECO:0000269|PubMed:1756734, ECO:0000269|PubMed:23071094,
CC       ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331,
CC       ECO:0000269|PubMed:28178239}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-glutamate + tRNA(Glu) = AMP + diphosphate + L-
CC         glutamyl-tRNA(Glu); Xref=Rhea:RHEA:23540, Rhea:RHEA-COMP:9663,
CC         Rhea:RHEA-COMP:9680, ChEBI:CHEBI:29985, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:78442, ChEBI:CHEBI:78520,
CC         ChEBI:CHEBI:456215; EC=6.1.1.17;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-proline + tRNA(Pro) = AMP + diphosphate + L-prolyl-
CC         tRNA(Pro); Xref=Rhea:RHEA:14305, Rhea:RHEA-COMP:9700, Rhea:RHEA-
CC         COMP:9702, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:60039,
CC         ChEBI:CHEBI:78442, ChEBI:CHEBI:78532, ChEBI:CHEBI:456215;
CC         EC=6.1.1.15; Evidence={ECO:0000269|PubMed:23263184,
CC         ECO:0000269|PubMed:24100331};
CC   -!- ACTIVITY REGULATION: Inhibited by halofuginone.
CC       {ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331}.
CC   -!- SUBUNIT: Homodimer (PubMed:24100331, PubMed:23263184). Part of the
CC       aminoacyl-tRNA synthetase multienzyme complex, also know as
CC       multisynthetase complex (MSC), that is composed of the tRNA ligases for
CC       Arg (RARS1), Asp (DARS1), Gln (QARS1), Ile (IARS1), Leu (LARS1), Lys
CC       (KARS1), Met (MARS1) the bifunctional ligase for Glu and Pro (EPRS1)
CC       and the auxiliary subunits AIMP1/p43, AIMP2/p38 and EEF1E1/p18
CC       (PubMed:24312579, PubMed:19131329, PubMed:19289464). Forms a linear
CC       complex that contains MARS1, EEF1E1, EPRS1 and AIMP2 that is at the
CC       core of the multisubunit complex (PubMed:26472928). Interacts with
CC       TARS3 (PubMed:24312579). Interacts with DUS2L (PubMed:15994936).
CC       Component of the GAIT complex which is composed of EPRS1, RPL13A and
CC       GAPDH. For human, the complex assembly seems to be a two-step process
CC       in which EPRS1 first associates with SYNCRIP to form a pre-GAIT complex
CC       which is deficient in GAIT element binding (PubMed:15479637). Interacts
CC       (phosphorylated at Ser-999) with SLC27A1; mediates the translocation of
CC       SLC27A1 from the cytoplasm to the plasma membrane thereby increasing
CC       the uptake of long-chain fatty acids (PubMed:28178239).
CC       {ECO:0000269|PubMed:15479637, ECO:0000269|PubMed:15994936,
CC       ECO:0000269|PubMed:19131329, ECO:0000269|PubMed:19289464,
CC       ECO:0000269|PubMed:19647514, ECO:0000269|PubMed:23263184,
CC       ECO:0000269|PubMed:24100331, ECO:0000269|PubMed:24312579,
CC       ECO:0000269|PubMed:26472928, ECO:0000269|PubMed:28178239}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-355315, EBI-355315;
CC       Q8IWL3:HSCB; NbExp=4; IntAct=EBI-355315, EBI-1805738;
CC       P41252:IARS; NbExp=7; IntAct=EBI-355315, EBI-355303;
CC       Q15046:KARS; NbExp=4; IntAct=EBI-355315, EBI-356367;
CC       O60506:SYNCRIP; NbExp=3; IntAct=EBI-355315, EBI-1024357;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10791971,
CC       ECO:0000269|PubMed:19289464}. Membrane {ECO:0000269|PubMed:28178239};
CC       Peripheral membrane protein {ECO:0000305|PubMed:19289464,
CC       ECO:0000305|PubMed:28178239}. Note=Translocates from cytosol to
CC       membranes upon phosphorylation at Ser-999.
CC       {ECO:0000269|PubMed:19289464, ECO:0000269|PubMed:28178239}.
CC   -!- DOMAIN: The WHEP-TRS domains are involved in RNA binding.
CC       {ECO:0000250|UniProtKB:Q7SIA2}.
CC   -!- PTM: Phosphorylated at Ser-886 by CDK5 (PubMed:19647514,
CC       PubMed:21220307). Phosphorylated at Ser-999 by RPS6KB1; triggers EPRS1
CC       release from the aminoacyl-tRNA synthetase multienzyme complex
CC       (PubMed:19647514, PubMed:21220307, PubMed:28178239). In monocytes, the
CC       IFN-gamma-induced sequential phosphorylation at Ser-886 and Ser-999
CC       releases EPRS1 from the aminoacyl-tRNA synthetase multienzyme complex,
CC       allowing its association with the GAIT complex. Phosphorylation at Ser-
CC       999 is specifically required for the RPL13A-mediated interaction of the
CC       GAIT complex with eIF4G (PubMed:19647514, PubMed:21220307).
CC       Phosphorylation at Ser-999 by RPS6KB1, is also induced by insulin
CC       through activation of the mTORC1 signaling pathway and promotes the
CC       interaction of EPRS1 with SLC27A1 (PubMed:28178239).
CC       {ECO:0000269|PubMed:19647514, ECO:0000269|PubMed:21220307,
CC       ECO:0000269|PubMed:28178239}.
CC   -!- DISEASE: Leukodystrophy, hypomyelinating, 15 (HLD15) [MIM:617951]: An
CC       autosomal recessive disorder characterized by hypomyelinating
CC       leukodystrophy with thinning of the corpus callosum. Clinical features
CC       include motor and cognitive impairment appearing in the first or second
CC       decade of life, dystonia, ataxia, spasticity, and dysphagia. Most
CC       patients develop severe optic atrophy, and some have hearing loss.
CC       {ECO:0000269|PubMed:29576217}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the class-I
CC       aminoacyl-tRNA synthetase family. Glutamate--tRNA ligase type 2
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the class-II
CC       aminoacyl-tRNA synthetase family. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be a glutaminyl-tRNA synthetase.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH15494.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH34797.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH46156.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH58921.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAS72877.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA30354.1; Type=Miscellaneous discrepancy; Note=Sequencing errors.; Evidence={ECO:0000305};
CC       Sequence=CAA38224.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CR933648; CAI45949.1; -; mRNA.
DR   EMBL; AC103590; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015494; AAH15494.1; ALT_SEQ; mRNA.
DR   EMBL; BC034797; AAH34797.1; ALT_SEQ; mRNA.
DR   EMBL; BC046156; AAH46156.1; ALT_SEQ; mRNA.
DR   EMBL; BC058921; AAH58921.1; ALT_SEQ; mRNA.
DR   EMBL; BC126275; AAI26276.1; -; mRNA.
DR   EMBL; BC136465; AAI36466.1; -; mRNA.
DR   EMBL; X54326; CAA38224.1; ALT_INIT; mRNA.
DR   EMBL; AY493416; AAS72877.1; ALT_INIT; mRNA.
DR   EMBL; X07466; CAA30354.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS31027.1; -.
DR   PIR; A38663; SYHUQT.
DR   RefSeq; NP_004437.2; NM_004446.2.
DR   PDB; 1FYJ; NMR; -; A=749-805.
DR   PDB; 4HVC; X-ray; 2.00 A; A/B=1003-1512.
DR   PDB; 4K86; X-ray; 2.40 A; A=1000-1512.
DR   PDB; 4K87; X-ray; 2.30 A; A=1000-1512.
DR   PDB; 4K88; X-ray; 2.62 A; A=1000-1512.
DR   PDB; 5A1N; X-ray; 2.10 A; A=1-175.
DR   PDB; 5A34; X-ray; 2.60 A; A/C/E/G=1-175.
DR   PDB; 5A5H; X-ray; 2.32 A; A/C/E/G=1-175.
DR   PDB; 5BMU; X-ray; 2.60 A; B/D/F/H=1-175.
DR   PDB; 5V58; X-ray; 2.59 A; A=1003-1512.
DR   PDB; 5VAD; X-ray; 2.36 A; A/B=998-1512.
DR   PDB; 5Y6L; X-ray; 2.90 A; C=1-175.
DR   PDB; 6IY6; X-ray; 3.60 A; E/F/K/L=1-157.
DR   PDBsum; 1FYJ; -.
DR   PDBsum; 4HVC; -.
DR   PDBsum; 4K86; -.
DR   PDBsum; 4K87; -.
DR   PDBsum; 4K88; -.
DR   PDBsum; 5A1N; -.
DR   PDBsum; 5A34; -.
DR   PDBsum; 5A5H; -.
DR   PDBsum; 5BMU; -.
DR   PDBsum; 5V58; -.
DR   PDBsum; 5VAD; -.
DR   PDBsum; 5Y6L; -.
DR   PDBsum; 6IY6; -.
DR   SMR; P07814; -.
DR   BioGrid; 108372; 241.
DR   CORUM; P07814; -.
DR   DIP; DIP-40825N; -.
DR   IntAct; P07814; 59.
DR   MINT; P07814; -.
DR   STRING; 9606.ENSP00000355890; -.
DR   BindingDB; P07814; -.
DR   ChEMBL; CHEMBL3873; -.
DR   DrugBank; DB03376; '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine.
DR   DrugBank; DB02510; '5'-O-(N-(L-Prolyl)-Sulfamoyl)Adenosine.
DR   DrugBank; DB02684; 5'-O-(N-(L-Cysteinyl)-Sulfamoyl)Adenosine.
DR   DrugBank; DB00142; Glutamic Acid.
DR   DrugBank; DB00172; Proline.
DR   MoonProt; P07814; -.
DR   iPTMnet; P07814; -.
DR   PhosphoSitePlus; P07814; -.
DR   SwissPalm; P07814; -.
DR   BioMuta; EPRS; -.
DR   DMDM; 288558855; -.
DR   CPTAC; CPTAC-71; -.
DR   CPTAC; CPTAC-72; -.
DR   EPD; P07814; -.
DR   jPOST; P07814; -.
DR   MassIVE; P07814; -.
DR   MaxQB; P07814; -.
DR   PaxDb; P07814; -.
DR   PeptideAtlas; P07814; -.
DR   PRIDE; P07814; -.
DR   ProteomicsDB; 52028; -.
DR   Ensembl; ENST00000366923; ENSP00000355890; ENSG00000136628.
DR   GeneID; 2058; -.
DR   KEGG; hsa:2058; -.
DR   UCSC; uc001hly.2; human.
DR   CTD; 2058; -.
DR   DisGeNET; 2058; -.
DR   GeneCards; EPRS1; -.
DR   HGNC; HGNC:3418; EPRS1.
DR   HPA; HPA026490; -.
DR   HPA; HPA030052; -.
DR   MalaCards; EPRS1; -.
DR   MIM; 138295; gene.
DR   MIM; 617951; phenotype.
DR   neXtProt; NX_P07814; -.
DR   OpenTargets; ENSG00000136628; -.
DR   PharmGKB; PA27837; -.
DR   eggNOG; KOG1147; Eukaryota.
DR   eggNOG; KOG4163; Eukaryota.
DR   eggNOG; COG0008; LUCA.
DR   eggNOG; COG0442; LUCA.
DR   GeneTree; ENSGT00550000074815; -.
DR   HOGENOM; CLU_001882_0_2_1; -.
DR   InParanoid; P07814; -.
DR   KO; K14163; -.
DR   OMA; WAFSIWE; -.
DR   OrthoDB; 809861at2759; -.
DR   PhylomeDB; P07814; -.
DR   TreeFam; TF300380; -.
DR   BRENDA; 6.1.1.15; 2681.
DR   Reactome; R-HSA-2408522; Selenoamino acid metabolism.
DR   Reactome; R-HSA-379716; Cytosolic tRNA aminoacylation.
DR   Reactome; R-HSA-6782315; tRNA modification in the nucleus and cytosol.
DR   SIGNOR; P07814; -.
DR   ChiTaRS; EPRS; human.
DR   EvolutionaryTrace; P07814; -.
DR   GeneWiki; EPRS; -.
DR   GenomeRNAi; 2058; -.
DR   Pharos; P07814; Tchem.
DR   PRO; PR:P07814; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P07814; protein.
DR   Bgee; ENSG00000136628; Expressed in parotid gland and 238 other tissues.
DR   ExpressionAtlas; P07814; baseline and differential.
DR   Genevisible; P07814; HS.
DR   GO; GO:0017101; C:aminoacyl-tRNA synthetase multienzyme complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:CAFA.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0097452; C:GAIT complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004818; F:glutamate-tRNA ligase activity; TAS:Reactome.
DR   GO; GO:0051020; F:GTPase binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004827; F:proline-tRNA ligase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0006424; P:glutamyl-tRNA aminoacylation; IEA:InterPro.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0006433; P:prolyl-tRNA aminoacylation; IDA:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; TAS:ProtInc.
DR   GO; GO:0140212; P:regulation of long-chain fatty acid import into cell; IMP:UniProtKB.
DR   GO; GO:0006418; P:tRNA aminoacylation for protein translation; TAS:Reactome.
DR   CDD; cd00778; ProRS_core_arch_euk; 1.
DR   Gene3D; 2.40.240.10; -; 2.
DR   Gene3D; 3.30.110.30; -; 1.
DR   Gene3D; 3.40.50.620; -; 1.
DR   Gene3D; 3.40.50.800; -; 1.
DR   HAMAP; MF_02076; Glu_tRNA_synth_type2; 1.
DR   HAMAP; MF_01571; Pro_tRNA_synth_type3; 1.
DR   InterPro; IPR002314; aa-tRNA-synt_IIb.
DR   InterPro; IPR001412; aa-tRNA-synth_I_CS.
DR   InterPro; IPR006195; aa-tRNA-synth_II.
DR   InterPro; IPR004154; Anticodon-bd.
DR   InterPro; IPR036621; Anticodon-bd_dom_sf.
DR   InterPro; IPR004526; Glu-tRNA-synth_arc/euk.
DR   InterPro; IPR000924; Glu/Gln-tRNA-synth.
DR   InterPro; IPR020058; Glu/Gln-tRNA-synth_Ib_cat-dom.
DR   InterPro; IPR020059; Glu/Gln-tRNA-synth_Ib_codon-bd.
DR   InterPro; IPR036282; Glutathione-S-Trfase_C_sf.
DR   InterPro; IPR004046; GST_C.
DR   InterPro; IPR004499; Pro-tRNA-ligase_IIa_arc-type.
DR   InterPro; IPR016061; Pro-tRNA_ligase_II_C.
DR   InterPro; IPR017449; Pro-tRNA_synth_II.
DR   InterPro; IPR033721; ProRS_core_arch_euk.
DR   InterPro; IPR020056; Rbsml_L25/Gln-tRNA_synth_N.
DR   InterPro; IPR011035; Ribosomal_L25/Gln-tRNA_synth.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   InterPro; IPR009068; S15_NS1_RNA-bd.
DR   InterPro; IPR000738; WHEP-TRS_dom.
DR   Pfam; PF00043; GST_C; 1.
DR   Pfam; PF03129; HGTP_anticodon; 1.
DR   Pfam; PF09180; ProRS-C_1; 1.
DR   Pfam; PF00749; tRNA-synt_1c; 1.
DR   Pfam; PF03950; tRNA-synt_1c_C; 1.
DR   Pfam; PF00587; tRNA-synt_2b; 1.
DR   Pfam; PF00458; WHEP-TRS; 3.
DR   PRINTS; PR00987; TRNASYNTHGLU.
DR   SMART; SM00946; ProRS-C_1; 1.
DR   SMART; SM00991; WHEP-TRS; 3.
DR   SUPFAM; SSF47060; SSF47060; 3.
DR   SUPFAM; SSF47616; SSF47616; 1.
DR   SUPFAM; SSF50715; SSF50715; 1.
DR   SUPFAM; SSF64586; SSF64586; 1.
DR   TIGRFAMs; TIGR00463; gltX_arch; 1.
DR   TIGRFAMs; TIGR00408; proS_fam_I; 1.
DR   PROSITE; PS00178; AA_TRNA_LIGASE_I; 1.
DR   PROSITE; PS50862; AA_TRNA_LIGASE_II; 1.
DR   PROSITE; PS00762; WHEP_TRS_1; 3.
DR   PROSITE; PS51185; WHEP_TRS_2; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Aminoacyl-tRNA synthetase; ATP-binding;
KW   Cytoplasm; Disease mutation; Leukodystrophy; Ligase; Membrane;
KW   Metal-binding; Methylation; Multifunctional enzyme; Neurodegeneration;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Protein biosynthesis;
KW   Reference proteome; Repeat; RNA-binding; Translation regulation; Zinc.
FT   CHAIN           1..1512
FT                   /note="Bifunctional glutamate/proline--tRNA ligase"
FT                   /id="PRO_0000119743"
FT   DOMAIN          749..805
FT                   /note="WHEP-TRS 1"
FT   DOMAIN          822..878
FT                   /note="WHEP-TRS 2"
FT   DOMAIN          900..956
FT                   /note="WHEP-TRS 3"
FT   NP_BIND         432..436
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         1152..1154
FT                   /note="ATP"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K87,
FT                   ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331"
FT   NP_BIND         1163..1164
FT                   /note="ATP"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K87,
FT                   ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331"
FT   NP_BIND         1237..1240
FT                   /note="ATP"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K87,
FT                   ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331"
FT   REGION          164..759
FT                   /note="Glutamate--tRNA ligase"
FT   REGION          760..956
FT                   /note="3 X 57 AA approximate repeats"
FT   REGION          959..991
FT                   /note="Charged"
FT   REGION          1007..1512
FT                   /note="Proline--tRNA ligase"
FT   REGION          1121..1123
FT                   /note="L-proline binding"
FT                   /evidence="ECO:0000244|PDB:4K87,
FT                   ECO:0000269|PubMed:24100331"
FT   MOTIF           204..214
FT                   /note="'HIGH' region"
FT   MOTIF           432..436
FT                   /note="'KMSKS' region"
FT   COMPBIAS        961..991
FT                   /note="Lys-rich"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00012"
FT   METAL           1448
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K86,
FT                   ECO:0000244|PDB:4K87, ECO:0000269|PubMed:23263184,
FT                   ECO:0000269|PubMed:24100331"
FT   METAL           1453
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K86,
FT                   ECO:0000244|PDB:4K87, ECO:0000244|PDB:4K88,
FT                   ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331"
FT   METAL           1495
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K86,
FT                   ECO:0000244|PDB:4K87, ECO:0000244|PDB:4K88,
FT                   ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331"
FT   METAL           1497
FT                   /note="Zinc"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K86,
FT                   ECO:0000244|PDB:4K87, ECO:0000244|PDB:4K88,
FT                   ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331"
FT   BINDING         211
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   BINDING         398
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   BINDING         1152
FT                   /note="L-proline"
FT                   /evidence="ECO:0000244|PDB:4K87,
FT                   ECO:0000269|PubMed:24100331"
FT   BINDING         1242
FT                   /note="L-proline"
FT                   /evidence="ECO:0000244|PDB:4K87,
FT                   ECO:0000269|PubMed:24100331"
FT   BINDING         1276
FT                   /note="ATP"
FT                   /evidence="ECO:0000244|PDB:4HVC, ECO:0000244|PDB:4K87,
FT                   ECO:0000269|PubMed:23263184, ECO:0000269|PubMed:24100331"
FT   MOD_RES         300
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         300
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         355
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         417
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         498
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         535
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         542
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         637
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         747
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         788
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         861
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CGC7"
FT   MOD_RES         872
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         882
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163"
FT   MOD_RES         885
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         886
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163, ECO:0000269|PubMed:19647514,
FT                   ECO:0000269|PubMed:21220307"
FT   MOD_RES         891
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         898
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:23186163"
FT   MOD_RES         998
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         999
FT                   /note="Phosphoserine; by RPS6KB1"
FT                   /evidence="ECO:0000269|PubMed:19647514,
FT                   ECO:0000269|PubMed:28178239"
FT   MOD_RES         1000
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         1152
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         1350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1503
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   VARIANT         296
FT                   /note="A -> P (in dbSNP:rs35999099)"
FT                   /id="VAR_037288"
FT   VARIANT         308
FT                   /note="D -> E (in dbSNP:rs2230301)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17974005, ECO:0000269|PubMed:1988429,
FT                   ECO:0000269|PubMed:3290852, ECO:0000269|Ref.5"
FT                   /id="VAR_037289"
FT   VARIANT         334
FT                   /note="Q -> H (in dbSNP:rs1063236)"
FT                   /evidence="ECO:0000269|PubMed:1988429,
FT                   ECO:0000269|PubMed:3290852, ECO:0000269|Ref.5"
FT                   /id="VAR_037290"
FT   VARIANT         339..1512
FT                   /note="Missing (in HLD15)"
FT                   /evidence="ECO:0000269|PubMed:29576217"
FT                   /id="VAR_080800"
FT   VARIANT         893
FT                   /note="P -> H (in dbSNP:rs5030751)"
FT                   /id="VAR_037291"
FT   VARIANT         913
FT                   /note="E -> G (in dbSNP:rs2230302)"
FT                   /id="VAR_057358"
FT   VARIANT         1043
FT                   /note="I -> V (in dbSNP:rs5030752)"
FT                   /evidence="ECO:0000269|PubMed:17974005"
FT                   /id="VAR_037292"
FT   VARIANT         1107
FT                   /note="S -> F (in dbSNP:rs12144752)"
FT                   /id="VAR_037293"
FT   VARIANT         1115
FT                   /note="P -> R (in HLD15; slightly decreased protein level;
FT                   does not affect multisynthetase complex assembly;
FT                   dbSNP:rs1288116010)"
FT                   /evidence="ECO:0000269|PubMed:29576217"
FT                   /id="VAR_080801"
FT   VARIANT         1126
FT                   /note="M -> T (in HLD15; unknown pathological significance;
FT                   small decrease in aminoacylation activity;
FT                   dbSNP:rs1474000585)"
FT                   /evidence="ECO:0000269|PubMed:29576217"
FT                   /id="VAR_080802"
FT   VARIANT         1160
FT                   /note="P -> S (in HLD15; unknown pathological significance;
FT                   dbSNP:rs898824971)"
FT                   /evidence="ECO:0000269|PubMed:29576217"
FT                   /id="VAR_080803"
FT   VARIANT         1399
FT                   /note="T -> N (in dbSNP:rs34559775)"
FT                   /id="VAR_037294"
FT   MUTAGEN         886
FT                   /note="S->A: Abolishes release from the aminoacyl-tRNA
FT                   synthetase multienzyme complex and association with the
FT                   GAIT complex upon interferon-gamma treatment. Abolishes
FT                   interaction with SYNCRIP."
FT                   /evidence="ECO:0000269|PubMed:23071094"
FT   MUTAGEN         886
FT                   /note="S->D: Not active in translation inhibition
FT                   (phosphomimetic) and abolishes GAIT complex association
FT                   with eiF4G. No effect on interaction with SYNCRIP."
FT                   /evidence="ECO:0000269|PubMed:23071094"
FT   MUTAGEN         999
FT                   /note="S->A: Not active in translation inhibition,
FT                   abolishes release from the aminoacyl-tRNA synthetase
FT                   multienzyme complex and association with the GAIT complex
FT                   upon interferon-gamma treatment."
FT                   /evidence="ECO:0000269|PubMed:23071094"
FT   MUTAGEN         999
FT                   /note="S->D: Active in translation inhibition
FT                   (phosphomimetic). No effect on GAIT complex association
FT                   with eiF4G."
FT                   /evidence="ECO:0000269|PubMed:23071094"
FT   MUTAGEN         1097
FT                   /note="F->A: Almost complete loss of prolyl-tRNA ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:24100331"
FT   MUTAGEN         1097
FT                   /note="F->W: No effect on prolyl-tRNA ligase activity.
FT                   Decreases inhibition by halofuginone."
FT                   /evidence="ECO:0000269|PubMed:24100331"
FT   MUTAGEN         1152
FT                   /note="R->K: No effect on prolyl-tRNA ligase activity.
FT                   Decreases inhibition by halofuginone."
FT                   /evidence="ECO:0000269|PubMed:24100331"
FT   MUTAGEN         1152
FT                   /note="R->L: Almost complete loss of prolyl-tRNA ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:24100331"
FT   CONFLICT        532
FT                   /note="K -> R (in Ref. 1; CAI45949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        594
FT                   /note="L -> F (in Ref. 4; CAA38224 and 5; AAS72877)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        943
FT                   /note="K -> E (in Ref. 1; CAI45949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1177..1179
FT                   /note="ATM -> VTV (in Ref. 1; CAI45949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1441
FT                   /note="K -> R (in Ref. 1; CAI45949)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..7
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   STRAND          10..12
FT                   /evidence="ECO:0000244|PDB:5A34"
FT   HELIX           15..24
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   TURN            25..27
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   STRAND          30..33
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   STRAND          39..43
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   STRAND          46..48
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           51..61
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           63..65
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           72..87
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   TURN            88..90
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           95..106
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   STRAND          110..113
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   STRAND          114..116
FT                   /evidence="ECO:0000244|PDB:5BMU"
FT   HELIX           119..129
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           132..139
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           145..155
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           158..167
FT                   /evidence="ECO:0000244|PDB:5A1N"
FT   HELIX           750..769
FT                   /evidence="ECO:0000244|PDB:1FYJ"
FT   HELIX           774..795
FT                   /evidence="ECO:0000244|PDB:1FYJ"
FT   TURN            1020..1022
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1024..1034
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1038..1040
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1042..1045
FT                   /evidence="ECO:0000244|PDB:4K86"
FT   STRAND          1047..1049
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1051..1070
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1080..1083
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1084..1087
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   TURN            1088..1090
FT                   /evidence="ECO:0000244|PDB:4K86"
FT   HELIX           1095..1100
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1102..1107
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1110..1118
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1120..1122
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1123..1133
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1137..1139
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1142..1151
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   TURN            1160..1162
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1165..1178
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1179..1198
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1206..1209
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   TURN            1212..1214
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1219..1229
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   TURN            1230..1233
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1234..1245
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1247..1252
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1255..1257
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1259..1261
FT                   /evidence="ECO:0000244|PDB:5VAD"
FT   STRAND          1265..1267
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1269..1276
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1278..1287
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   TURN            1297..1299
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1303..1308
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1313..1315
FT                   /evidence="ECO:0000244|PDB:4K87"
FT   HELIX           1317..1336
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1341..1343
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1347..1349
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1351..1360
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1364..1369
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1371..1376
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1378..1383
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   TURN            1384..1386
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1389..1393
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1394..1396
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1397..1423
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1424..1426
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1430..1438
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1442..1447
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   HELIX           1451..1462
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1477..1484
FT                   /evidence="ECO:0000244|PDB:4HVC"
FT   STRAND          1498..1501
FT                   /evidence="ECO:0000244|PDB:4K87"
FT   STRAND          1504..1509
FT                   /evidence="ECO:0000244|PDB:4HVC"
SQ   SEQUENCE   1512 AA;  170591 MW;  2CE4311076719403 CRC64;
     MATLSLTVNS GDPPLGALLA VEHVKDDVSI SVEEGKENIL HVSENVIFTD VNSILRYLAR
     VATTAGLYGS NLMEHTEIDH WLEFSATKLS SCDSFTSTIN ELNHCLSLRT YLVGNSLSLA
     DLCVWATLKG NAAWQEQLKQ KKAPVHVKRW FGFLEAQQAF QSVGTKWDVS TTKARVAPEK
     KQDVGKFVEL PGAEMGKVTV RFPPEASGYL HIGHAKAALL NQHYQVNFKG KLIMRFDDTN
     PEKEKEDFEK VILEDVAMLH IKPDQFTYTS DHFETIMKYA EKLIQEGKAY VDDTPAEQMK
     AEREQRIDSK HRKNPIEKNL QMWEEMKKGS QFGQSCCLRA KIDMSSNNGC MRDPTLYRCK
     IQPHPRTGNK YNVYPTYDFA CPIVDSIEGV THALRTTEYH DRDEQFYWII EALGIRKPYI
     WEYSRLNLNN TVLSKRKLTW FVNEGLVDGW DDPRFPTVRG VLRRGMTVEG LKQFIAAQGS
     SRSVVNMEWD KIWAFNKKVI DPVAPRYVAL LKKEVIPVNV PEAQEEMKEV AKHPKNPEVG
     LKPVWYSPKV FIEGADAETF SEGEMVTFIN WGNLNITKIH KNADGKIISL DAKLNLENKD
     YKKTTKVTWL AETTHALPIP VICVTYEHLI TKPVLGKDED FKQYVNKNSK HEELMLGDPC
     LKDLKKGDII QLQRRGFFIC DQPYEPVSPY SCKEAPCVLI YIPDGHTKEM PTSGSKEKTK
     VEATKNETSA PFKERPTPSL NNNCTTSEDS LVLYNRVAVQ GDVVRELKAK KAPKEDVDAA
     VKQLLSLKAE YKEKTGQEYK PGNPPAEIGQ NISSNSSASI LESKSLYDEV AAQGEVVRKL
     KAEKSPKAKI NEAVECLLSL KAQYKEKTGK EYIPGQPPLS QSSDSSPTRN SEPAGLETPE
     AKVLFDKVAS QGEVVRKLKT EKAPKDQVDI AVQELLQLKA QYKSLIGVEY KPVSATGAED
     KDKKKKEKEN KSEKQNKPQK QNDGQRKDPS KNQGGGLSSS GAGEGQGPKK QTRLGLEAKK
     EENLADWYSQ VITKSEMIEY HDISGCYILR PWAYAIWEAI KDFFDAEIKK LGVENCYFPM
     FVSQSALEKE KTHVADFAPE VAWVTRSGKT ELAEPIAIRP TSETVMYPAY AKWVQSHRDL
     PIKLNQWCNV VRWEFKHPQP FLRTREFLWQ EGHSAFATME EAAEEVLQIL DLYAQVYEEL
     LAIPVVKGRK TEKEKFAGGD YTTTIEAFIS ASGRAIQGGT SHHLGQNFSK MFEIVFEDPK
     IPGEKQFAYQ NSWGLTTRTI GVMTMVHGDN MGLVLPPRVA CVQVVIIPCG ITNALSEEDK
     EALIAKCNDY RRRLLSVNIR VRADLRDNYS PGWKFNHWEL KGVPIRLEVG PRDMKSCQFV
     AVRRDTGEKL TVAENEAETK LQAILEDIQV TLFTRASEDL KTHMVVANTM EDFQKILDSG
     KIVQIPFCGE IDCEDWIKKT TARDQDLEPG APSMGAKSLC IPFKPLCELQ PGAKCVCGKN
     PAKYYTLFGR SY
//
